Pictilisib (GDC-0941) is an orally accessible pan class I PI3K inhibitor currently being investigated in clinical researches for the treatment of progressive breast cancer.42, 43Pictilisib nonspecifically inhibits all four isoforms of PI3K because it binds to the ATP (adenosine triphosphate)-binding pocket. The gene discussed is PIK3CA; the disease is breast cancer.